Course Type: On-Demand Webcourse 
Number of Credits: 1
Credit Type: CME/MOC/MIPS

Get Started

Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy will review how to use the risk assessment tool, and the 2018 LDL-C guidelines, including the role of the nonstatin agents ezetimibe and PCSK9 inhibitors. Expert faculty will discuss the role of bempedoic acid, an agent recently approved for LDL-C management, as well as results from trials of inclisiran, an agent in late-stage development.


FACULTY

Rachel M. Bond, MD, FACC
System Director, Women’s Heart Health
Dignity Health, Arizona
Chandler, AZ

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute
Providence St. Joseph Health
Portland, OR
Adjunct Faculty, Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins Hospital
Baltimore, MD

Get Started

 


PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

SUPPORTER

This activity is supported by educational funding provided by Amgen and Esperion.